Suggestions
Anita Venkiteswaran
Healthcare Executive & Investor
Anita Venkiteswaran
Anita Venkiteswaran is an experienced healthcare and financial services entrepreneurial C-suite executive with a demonstrated track record of growing businesses over the last 14+ years.1 She currently serves as the Chief Growth Officer at HBS Alumni Angels of Greater New York and the Chief Operating Officer at Doppler Veterinary Network.12
Professional Experience
- Chief Growth Officer at HBS Alumni Angels of Greater New York1
- Chief Operating Officer & Chief Growth Officer at Doppler Veterinary Network (since February 2022)1
- Principal at Focus Financial Partners (2016-2019)1
- Vice President at Focus Financial Partners (2013-2016)1
- Associate at CI Capital Partners (2012-2013)1
- MBA Summer Intern at Novartis (2011)1
- Associate and Senior Analyst at Audax Private Equity (2008-2010)1
- Business Analyst at McKinsey & Company (2006-2008)1
Education
- MBA from Harvard Business School (2010-2012)1
- B.Tech (Hons) in Biotechnology & Biochemical Engineering from Indian Institute of Technology, Kharagpur (2002-2006)1
Expertise
- Strategy, operations, M&A, strategic partnerships, capital raising, and new business launches across start-ups and large institutions1
- Sourcing, evaluating, executing and managing RIA partnerships/transactions1
- Providing growth-oriented strategic, operational and M&A expertise post transaction1
- Ideating, launching and growing new business lines1
Highlights
I am delighted to share that I will be joining Health Tech Challengers 2021 as a jury member. It’s an initiative that brings top healthcare and health tech startups to compete for global exposure and an equity-free money prize. If you have a business that is changing the game in the healthcare sector, don’t miss your chance to take part. Only a few days left to apply! Apply by September 10: https://lnkd.in/gh9xD5Xa
The last week has been a super exciting one for the Roivant Sciences family with 2 FDA approvals -
- ORGOVYX™ (relugolix), the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for advanced prostate cancer at Myovant Sciences (read more at http://ow.ly/Db8m50CPJrQ)
- GEMTESA® (vibegron) 75 mg tablets for the treatment of patients with overactive bladder (OAB) at Urovant Sciences, Inc. (read more at https://lnkd.in/dg78zpN)
